178 related articles for article (PubMed ID: 1352772)
1. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
2. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
[TBL] [Abstract][Full Text] [Related]
3. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity.
Stern DF; Heffernan PA; Weinberg RA
Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
5. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
Narasimhan V; Hamill O; Cerione RA
FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469
[TBL] [Abstract][Full Text] [Related]
6. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K
EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807
[TBL] [Abstract][Full Text] [Related]
7. Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Mikami Y; Davis JG; Dobashi K; Dougall WC; Myers JN; Brown VI; Greene MI
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7335-9. PubMed ID: 1354355
[TBL] [Abstract][Full Text] [Related]
8. A subdomain in the transmembrane domain is necessary for p185neu* activation.
Cao H; Bangalore L; Bormann BJ; Stern DF
EMBO J; 1992 Mar; 11(3):923-32. PubMed ID: 1347745
[TBL] [Abstract][Full Text] [Related]
9. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
Connelly PA; Stern DF
Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.
Stern DF; Kamps MP; Cao H
Mol Cell Biol; 1988 Sep; 8(9):3969-73. PubMed ID: 2464744
[TBL] [Abstract][Full Text] [Related]
11. Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro.
Yamada K; Goncalves E; Kahn CR; Shoelson SE
J Biol Chem; 1992 Jun; 267(18):12452-61. PubMed ID: 1352286
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain.
Wides RJ; Zak NB; Shilo BZ
Eur J Biochem; 1990 May; 189(3):637-45. PubMed ID: 1972062
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.
Shu HK; Pelley RJ; Kung HJ
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168
[TBL] [Abstract][Full Text] [Related]
15. Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors.
McGlynn E; Becker M; Mett H; Reutener S; Cozens R; Lydon NB
Eur J Biochem; 1992 Jul; 207(1):265-75. PubMed ID: 1321046
[TBL] [Abstract][Full Text] [Related]
16. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene.
Bargmann CI; Weinberg RA
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5394-8. PubMed ID: 2899890
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.
Bargmann CI; Weinberg RA
EMBO J; 1988 Jul; 7(7):2043-52. PubMed ID: 2901345
[TBL] [Abstract][Full Text] [Related]
18. Differential processing and turnover of the oncogenically activated neu/erb B2 gene product and its normal cellular counterpart.
Huang SS; Koh HA; Konish Y; Bullock LD; Huang JS
J Biol Chem; 1990 Feb; 265(6):3340-6. PubMed ID: 1968062
[TBL] [Abstract][Full Text] [Related]
19. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
20. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.
Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ
J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
